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Background/Aims: Newly developed and potent antiviral agents suffer from the problem of drug resistance. Multidrug 
resistance is a major impediment in the treatment of patients with chronic hepatitis B (CHB). In line with American 
Association for the Study of Liver Diseases guidelines, adefovir dipivoxil (ADV) add-on therapy is recommended in the 
case of lamivudine resistance, while tenofovir disoproxil fumarate (TDF) is recommended for ADV or entecavir (ETV) 
resistance. TDF is currently not available in Korea. ADV+ETV combination therapy may be a viable alternative to TDF in 
patients with either ADV or ETV resistance. However, the efficacy of ADV+ETV combination therapy in patients with CHB 
and multidrug resistance is unclear. This study investigated the efficacy of ADV+ETV combination therapy in patients with 
multidrug resistance. Methods:  Twenty-five patients were enrolled and were administered ADV+ETV combination 
therapy for at least 6 months. Blood was drawn at baseline and at 3, 6, 9, and 12 months after commencing treatment, 
and the following blood parameters were analyzed: alanine transaminase, hepatitis B e-antigen (HBeAg), anti-hepatitis B 
e-antigen, and hepatitis B virus (HBV) DNA levels. The initial virological response (IVR) was defined as an HBV DNA level 
of <4 log10 copies/mL after 6 months of combination therapy. Results: The IVR rate was 76%. The proportion of patients 
with a high viral load (≥5.0 log) dropped from 76% at baseline to only 5% after 6 months of treatment. The biochemical 
response rate during the first 6 months was 71%. HBeAg was lost in 2 patients (10%). Conclusions:  ADV+ETV 
combination therapy induced a good IVR in CHB patients who were refractory to more than 2 antiviral agents. This 
regimen may be a good alternative to TDF in Korea, where that drug is not available. (Korean J Hepatol 2012;18:75-83)
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INTRODUCTION
About 350 million people world-wide are chronically 
infected with hepatitis B (HBV),
1,2 which can result in 
severe liver disease that eventually progresses to cirrhosis 
and hepatocellular carcinoma.
3,4 To date, interferon alpha 
and five nucleos(t)ide analogs (NAs), namely,  lamivudine 
(LAM), adefovir (ADV), entecavir (ETV), clevudine and 
telbivudine have been approved for the treatment of chronic 
hepatitis B (CHB) in Korea. In South-East Asia, oral 
nucleosides are prescribed more frequently than interferon 
because genotype C is common.
5 Drug resistance often 
results from prolonged oral nucleoside treatment. LAM was 
first released for general use in Korea in 1999. Thereafter, 
the remaining four antiviral agents were introduced in a 
sequential manner. ETV resistance occurs frequently in 
patients with LAM resistance.
6 Moreover, LAM-resistant 
patients with CHB sometimes also exhibit ADV resistance, 
although ADV is thought to be a good rescue therapy 
for LAM resistance.
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telbivudine (LdT) are very similar to LAM in terms of 
their chemical structure and resistance profile. Thus, an 
alternative treatment for patients with ADV or ETV 
resistance is needed. One possible alternative is ADV-ETV 
combination therapy. This approach has the advantage 
that the drugs may synergize in terms of efficacy while 
preventing the emergence of mutants. Its disadvantage is its 
high cost. 
The present study investigated the efficacy of ADV-ETV 
combination therapy in patients with CHB who did not 
respond to ADV add-on or high dose (1 mg) ETV therapy. In 
addition, factors that promoted an initial virological response 
(IVR) to the combination therapy were identified. 
MATERIALS AND METHODS
Subjects
In total, 25 patients with nucleoside-refractory CHB were 
enrolled in the study. All patients exhibited virological 
breakthrough (VBT) before starting combination therapy, as 
defined by an increase in HBV DNA levels of at least 1 
log10copies/mL (log) from the nadir during rescue therapy 
such as ADV add-on and high-dose ETV therapy. Patients 
were considered to be refractory if they had an inadequate 
virological response with or without documented genotypic 
mutations while they were receiving antiviral therapy. An 
inadequate virological response was defined as an HBV 
DNA level >4 log at 6 months of rescue therapy. The 
patients were followed up regularly at 3-month intervals.
The inclusion criteria were as follows: patients were 
positive for hepatitis B surface antigen (HBsAg) at least 1 
year before commencing combination therapy, had HBV 
DNA level >4 log, and received both ADV and ETV once 
daily for at least 6 months. Several biochemical parameters 
and HBV DNA levels were tested at baseline and every 
3 months during combination therapy. 
None of the patients were co-infected with hepatitis C 
virus or human immunodeficiency virus or  concomitant 
liver diseases such as alcoholic liver disease or autoimmune 
liver disease. The IVR was defined as HBV DNA levels 
below 4 log at 6 months of combination therapy. The 
continued  virological response (CVR) was defined as HBV 
DNA levels below 4 log after the 6 month time point.
Analysis of virological markers
Routine biochemical tests were performed during therapy 
by using standard procedures. HBsAg, hepatitis B e-antigen 
(HBeAg), and anti-hepatitis B e-antigen (anti-HBe) were 
tested by using a commercial radioimmunoassay kit (Abbott 
Laboratories, Chicago, IL, USA). HBV DNA levels were 
determined quantitatively by real time PCR (Roche Molecular 
Systems, Branchburg, NJ, USA) that had a detection limit of 
70 copies/mL. The HBV genotype was not examined 
because all patients were known to have genotype C.
8,9
 
Genotypic analysis
All baseline patient samples were analyzed for genotypic 
resistance before starting the combination therapy and at the 
end of treatment. On-treatment was defined as the time point 
just before starting the ADV-ETV combination therapy. 
Off-treatment was defined as the end of combination therapy. 
Moreover, when VBT was observed, patient samples were 
analyzed again to identify the mutations that were associated 
with the genotypic resistance. Genotypic resistance was 
investigated by restriction fragment mass polymorphism 
analysis, as described previously by Lee et al (Green-Cross 
Medical Laboratories, Giheung, Korea).
10
Statistical analysis
Statistical testing was performed by using SPSS version 
12 (SPSS Inc., Chicago, IL, USA). The data are reported as 
median (range). The HBV DNA data were logarithmically 
transformed prior to analysis. Continuous variables were 
compared by using the Mann-Whitney U test and Student’s t 
test. Categorical data were compared by using the Pearson χ
2 
test or Fisher’s exact test. The cumulative probability of 
achieving CVR was estimated by using the Kaplan-Meier 
method. Factors associated with an IVR were analyzed by 
univariate and multivariate analysis. A P-value less than 
0.05 was considered to be statistically significant.
RESULTS
Baseline characteristics
The study population comprised 25 nucleoside-refractory 
patients; with CHB who had previously shown established 
drug resistance or persistent VBT in at least two measu-
rements. Twenty patients were men and the median age was Hee Bok Chae, et al. ADV and ETV combination therapy  77
Table 1. Baseline characteristics of nucleoside-refractory patients with chronic hepatitis B virus (HBV) infection (n=25)
Characteristic 
Median age, years (min-max) 39 (25-64)
No. of males (%) 20 (80)
No. of HBeAg-positive patients (%) 20 (80)
No. with cirrhosis (%) 13 (52)
Median AST, IU/L (min-max) 36 (18-403)
Median ALT, IU/L (min-max) 41 (15-451)
Median albumin, g/dL (min-max) 4.6 (4.0-5.2)
Median total bilirubin, mg/dL (min-max) 0.7 (0.4-10.3)
Median HBV DNA, log10IU/mL (min-max) 5.8 (4.1-9.0)
Median duration of ETV plus ADV therapy, months n (min-max) 12 (6-24)
Previous failures to
  2  N A s  ( n ,  % ) 14 (56)
    LAM followed by ADV monotherapy 1 (4)
    LAM followed by ETV monotherapy 6( 2 4 )
    LAM followed by LAM+ADV combination therapy 7 (28)
  3  N A s  ( n ,  % ) 11 (44)
    LAM, ADV and ETV monotherapies sequentially (n, %) 4 (16)
    LAM, ETV and LAM+ADV combination sequentially 4( 1 6 )
    LAM, LAM+ADV combination and ETV monotherapy sequentially 3 (12)
Resistance mutations to
  L A M  ( n ,  % ) 12 (48)
    M 2 0 4 V / I + L 1 8 0 M 8( 3 2 )
    M 2 0 4 I 4( 1 6 )
  LAM and ADV (n, %) 4( 1 6 )
    M204V/I+L180M+A181V/T 2 (8)
    M204I+A181V/T+N236T 1( 4 )
    A181V/T+N236T
* 1( 4 )
  LAM and ETV 6( 2 4 )
    M204V/I+L180M+T184 2 (8)
    M204V/I+L180M+S202 4( 1 6 )
*The patient who had been referred due to a high viral load during lamivudine (LAM) plus adefovir dipivoxil (ADV) combination 
treatment and had previously had a LAM-resistant mutation. 
HBeAg, hepatitis B e-antigen; AST, aspartate aminotransferase; ALT, alanine aminotrasferase; HBV, hepatitis B virus; ETV, 
entecavir; ADV, adefovir dipivoxil; LMV, lamivudine; NAs, nucleos(t)ide analogues.
39 (25-64) (Table 1). Thirteen patients (52%) had cirrhosis 
and 20 patients (80%) were positive for HBeAg. The median 
length of treatment with ADV-ETV combination therapy 
was 12 (6-24) months. 
All patients had previously failed to respond to LAM 
monotherapy. All patients had taken at least two NAs. 
Fourteen patients (56%) had failed to respond to two NAs 
(LAM and either ADV or ETV) and 11 (54%) had failed to 
respond to three NAs (LAM, ADV and ETV).
Profiles of genotypic resistance at baseline and 
after the study time point
On-treatment
At the start of ADV-ETV combination therapy, 12 78  The Korean Journal of Hepatology Vol. 18. No. 1, March 2012
Table 2. Genotypic resistance profiles at the on-treatment and off-treatment time points 
Antiviral agent (n) On-treatment
* (n=21) Off-treatment (n=21)
ADV resistance (3) M204I+A181+N236 (2) M204I (1), ND (1)
L180M+M204V+A181T (1) L180M+M204V (1)
ETV resistance (5) L180M+M204V+S202G (3) L180M+M204V+S202G (2), Wild type (1)
L180M+M204V+T184I/A (2) L180M+M204V+T184I/A (2)
LAM resistance (10) M204V+L180M (7) M204V+L180M (5), ND (2)
M204I (3) M204I (3)
Wild type (3) Wild type (3) Wild type (3)
*The number of all patients were 25, but the blood samples of the off-treatment time point in four patients were not available. 
ND, not detectable; ADV, adefovir dipivoxil; ETV, entecavir; LAM, lamivudine.
patients (48%) had documented resistance mutations to 
LAM only, four (16%) to LAM and ADV (rtA181V/T 
and/or rtN236T), and six (24%) to LAM and ETV (rtT184 or 
rtS202). Mutations to NAs were not documented in three 
patients (12%) They had had VBT during the previous LAM 
treatment period and had a persistent high viral load during 
ADV add-on or ETV monotherapy. The HBV DNA levels 
of the three patients at baseline were 6.4, 5.7 and 4.5 log. 
All three patients had received LAM followed by ETV 
monotherapy.
Off-treatment
In the off-treatment time point, four samples were not 
available. Therefore, the data of 21 patients who had both 
samples at on- and off-treatment time points were analyzed. 
The HBV DNA was not detectable in three samples at 
off-treatment time point.
ADV resistance (three patients): Three patients had ADV 
and LAM resistance at the on-treatment time point. ADV 
resistance had disappeared at the off-treatment time point in 
three patients including one patient whose HBV DNA was 
undetectable.
ETV resistance (five patients): Four of five patients with 
both ETV resistance on-treatment had the same profile 
at the off-treatment time point. One patient had a changed 
resistance profile after the treatment, namely, ETV resistance 
was lost and only LAM resistance remained. 
LAM resistance (ten patients): The LAM resistance was 
maintained during the treatment. But two patients who had 
YVDD mutant at the on-treatment time point achieved 
complete virological response.
Wild type (three patients): The three patients with wild 
type at on-treatment did not acquire any genotypic resistance 
during the treatment period. The HBV DNA levels of these 
three patients decreased to ≤3.3 log (Table 2).
Virological and biochemical responses to 
combination therapy
From the start to 6 months of treatment, the proportion of 
patients with fewer than 4 log rose from 0 to 76%. However, 
the CVR at 9 months of treatment dropped 54%. The median 
pre-treatment HBV DNA level of all patients was 5.7 log 
(4.5-9.0). Fourteen patients had elevated alanine aminotran-
sferase (ALT) at baseline (Table 3). After 3 and 6 months of 
ADV-ETV combination therapy, respectively, three (12%) 
and four (16%) of the patients had undetectable HBV DNA 
levels, that is, complete virological response as determined 
by a PCR assay whose minimum detection limit was <70 
copies/mL. 
Nineteen of the 25 patients (76%) had an IVR (Table 3) 
(Fig. 1). Of the 20 patients who were HBeAg-positive 
at baseline, two (10%) lost HBeAg during ADV-ETV 
combination therapy at 10.5 months on average (Table 3). 
The graph of the cumulative CVR was steep during the 
early treatment period. After 6 months of treatment, the 
slope of the curve was gentle (Fig. 2). The patients with and 
without IVR did not differ significantly in any of the clinical 
variables, although the patients with IVR to have a lower 
baseline HBV DNA level (P=0.052) (Table 4).
DISCUSSION
Combination therapy was moderately efficacious for 
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Table 3. Virological, serological, and biochemical responses to combination therapy after 3, 6, 9, and 12  months of 25 nucleoside- 
resistant patients with chronic HBV infection
Baseline 
(n=25)
Month 3 
(n=25)
Month 6 
(n=25)
Month 9 
(n=21)
Month 12 
(n=13)
No. with HBV DNA, levels that were undetectable 0 3 4 3 3
<3.3 log10copies/mL 0 5 6 6 3
3.3-3.9 log10copies/mL 0 4 9 7 1
4.0-4.9 log10copies/mL 6 9 3 4 5
≥5.0 log10copies/mL 19 4 3 1 1
Median ALT, IU/L (min-max) 41 (15-451) 33.5 (23-69) 35 (21-87) 31 (21-57) 24 (12-75)
No. of HBeAg-positive patients who lost expression  2 (10%)
No. of patients who showed virological breakthrough 2
*
* The virological breakthrough in two patients occurred at 6 and 15 months, respectively.
HBV, hepatitis B virus; HBeAg, hepatitis B e antigen; ALT, alanine aminotransferase.
n 2 52 52 52 11 3
Median 
(range)
5.8
(4.1, 9.0)
4.0
(1.0, 6.0)
3.6
(1.0, 5.7)
3.5
(1.0, 5.5)
3.5
(1.0, 5.3)
HBV DNA 0 48 76 76 54
<4 log10copies/mL (%)
Figure 1. Distribution of nucleoside-resistant patients with chronic
hepatitis B virus (HBV) infection relative to their HBV DNA 
levels. All patients received combination treatment with 
entecavir (ETV) and adefovir (ADV). The log HBV DNA levels 
indicated on the y axis reflect all observations within that 
exponent. HBV DNA levels of <70  copies/mL could not be 
detected by polymerase chain reaction analysis. The proportion 
of patients with a high viral load dropped from 76% at baseline 
to 5% after 9  months of treatment. 
Figure 2. Cumulative probability of achieving a continued virological
response (CVR), defined as HBV DNA < 4 log10copies/mL after 
6 months of ETV+ADV combination treatment. The cumulative 
probabilities of CVR at months 1, 3, 6, 9, 12, and 15 were 26%, 
43%, 70%, 74%, 78%, and 85%, respectively; there were 22, 
17, 13, 7, 6, and 3 patients at these time points.
study. The IVR rate was 76%. Moreover, the proportion of 
patients who had high viral loads (≥5.0 log) dropped from 
76% at baseline to 5% after 6 months of treatment. Two 
patients (10%) lost HBeAg, and the biochemical response 
rate after the first 6 months of treatment was 76%. 
With regard to the IVR in this study, most of the patients 
who had high viral loads at baseline developed intermediate 
or low viral loads after combination therapy. While an 
IVR of 76% may not appear to be particularly high, it can 
actually be considered to be a good response when one 
realizes that these patients are multi-drug resistant patients 
with CHB who previously responded poorly to mono- 
therapies with all other oral NAs. 
CVR was defined as the HBV DNA levels below 4 log 
after the 6 month time point. The theoretical background of 80  The Korean Journal of Hepatology Vol. 18. No. 1, March 2012
Table 4. Baseline factors associated with an initial virological response (IVR)
Patients with IVR 
(n=19) (Group 1)
Patients without IVR
(n=6) (Group 2)
P-value
Median age, years (min-max) 48 (25-64) 57 (41-64) 0.14
No. of males (% of 25) 14 (74) 5( 5 0 ) 0.29
Mean serum HBV DNA level 
  Baseline, log10copies/mL (±SD) 5.7 (1.1) 7.1 (1.3) 0.052
  Months 6, log10copies/mL (±SD) 2.9 (1.1) 4.9 (0.5) 0.001
Mean change in serum HBV DNA level
  Months 3, log10copies/mL (±SD) 2.3 (1.7) 2.6 (1.3) 0.64
  Months 6, log10copies/mL (±SD) 2.9 (1.6) 2.2 (1.0) 0.22
No. of patients with HBV DNA levels, log10copies/mL
  < 7 . 0  l o g
* 16 5 0.13
  ≥7.0 log 9 1
Median AST (range) 36 (18-403) 38.5 (29-48) 0.87
Median ALT (range) 49 (15-451) 41 (16-72) 0.50
No. of HBeAg-positive patients (%) 16 (84) 4( 6 7 ) 0.56
No. with cirrhosis (%) 8 (42) 5 (83) 0.16
No. with biochemical response (%) 15 (79) 4( 6 7 ) 0.61
†Previous failures to <3 NAs 9 (47) 4 (67) 0.65
*This standard was taken from Cho et al
14; 
† Number of patients who were exposed to less than 3 NAs.
HBV DNA, hepatitis B virus DNA; IVR, initial virological response; NAs, nucleos(t)ide analogues; AST, aspartate transaminase; 
ALT, alanine transaminase; HBeAg, hepatitis B e-antigen.
this definition was originated from the previous studies. Lim 
et al defined the virological response as the same level.
11 The 
patients exposed to less NAs showed better treatment 
response. Lai et al
12 suggested that HBV DNA suppression 
should continue until the level decreases to less than 10
4 
copies/mL to prevent the development of complication. 
The CVR dropped from 76% at 6 months to 54% at 9 
months (Fig. 1). This is likely to be due to a blip pheno-
menon: blips can be defined as small fluctuations in HBV 
DNA levels that do not represent. Another reason was that 
the four patients with a good response dropped out of the 
study after 9 months because of the financial burden of the 
drugs. Actually, their HBV DNA levels at 6 months were 
3.2, 3.0, 2.0 and 1.0 log, respectively.
The cumulative probability of achieving CVR was shown 
by Figure 2. Kaplan-Meier analysis could be applied only if 
rebound HBV DNA levels after CVR were not observed in 
any of the patients during the observation period. Therefore, 
two patients with breakthroughs at 6 and 15 months, 
respectively, were excluded for Kaplan Meier analysis. We 
strongly suspect that these two patients showed poor 
compliance at these time points.
The sequential use of NAs monotherapies increases the 
risk of selection of multi-drug resistant strains.
13 As a result, 
the development of multi-drug resistance to LAM, ADV and 
ETV is becoming a significant problem in Korea.
14 
Combination therapy with ETV and tenofovir has been 
recommended for the treatment of patients who are resistant 
to LAM and ADV.
15 However, since tenofovir is currently 
not available in Korea, we speculated that ADV-ETV 
combination therapy may be a good alternative for patients 
with multi-drug resistance. However, Korean government 
insurance only permits the use of one antiviral agent in 
principle, which means that combination therapy places a 
considerable financial burden on patients in Korea. Drug 
adherence should be approached as a social problem rather 
than as a patient’s problem.
Baseline clinical prognostic factors that could predict IVR Hee Bok Chae, et al. ADV and ETV combination therapy  81
or CVR could not be identified. However, if the patients 
were divided into two groups according to whether they 
exhibited a decrease in HBV DNA by more than 2 log after 6 
months of treatment, only age differed significantly between 
the two groups upon univariate analysis (data not shown). 
Multi-variate analysis was performed for four significant 
factors (P-value <0.1 in univariate analysis). However, none 
of these factors were proven to be prognostic factors for IVR 
upon multi-variate analysis (data not shown). Another study 
showed that patients who were refractory to ADV and who 
achieved IVR with ETV monotherapy had higher baseline 
ALT and AST levels than those who did not achieve IVR.
14 
A recent study also showed that low pre-treatment HBV 
DNA levels and previous exposure to fewer NAs were 
associated with a virological response.
11 
The loss of HBeAg or a biochemical response during the 
early treatment period could not be analyzed because too 
few of the patients had HBeAg (n=20) or high ALT levels 
(n=16) at baseline. One patient exhibited a biochemical 
VBT after 15 months of treatment. This patient confessed 
that he had sometimes failed to take his medication around 
15 months after treatment. A new report about medication 
compliance that was published recently found that nine of 10 
patients who experienced an initial VBT, but did not have 
confirmed genotypic resistance, had undetectable HBV 
DNA levels at the most recent follow-up, which was on 
average 7 months after the initial VBT. These data suggest 
that medication noncompliance can be a common cause of 
VBT.
16
With regard to the genotypic resistance data of the present 
study, the genotypic resistance profile at the on-treatment 
time point was compared to that at the off-treatment time 
point. Mutations associated with LAM and ETV resistance 
were maintained in four of five patients, but ADV resistance 
had disappeared in three patients by the off-treatment time 
point. We speculate that ETV can somehow control 
ADV-resistant viruses, but ADV cannot control the virus 
with ETV-and LAM-resistant viruses. Indeed, Reijnders et 
al
17 reported that viruses with ADV- resistant mutations are 
expected to remain sensitive to ETV. Moreover, in vitro 
study reported that viruses with the ADV-resistance 
rtN236T mutation remains sensitive to ETV, albeit with a 
<3-fold change in IC50, while viruses with the ADV- 
resistance rt181V/T mutations remain completely sensitive 
to ETV.
18,19
The limitations of the present study were, first, that the 
follow-up period was short. Second, drug adherence in the 
patients was not checked. The three patients who had taken 
ETV showed an inadequate response to the ADV-ETV 
combination therapy and we suspect poor drug adherence in 
these patients. Third, four patients dropped out because of 
the economic burden of the drug regimen. Two patients 
completed 6 months of treatment, and the other two patients 
completed 9 months of treatment. Finally, the present study 
was retrospective.
In conclusion, patients who experienced ADV or ETV 
resistance after becoming refractory to LAM showed a good 
IVR in response to ADV-ETV combination therapy. This 
combination therapy appeared to be more effective for 
ADV-resistance mutations than ETV resistance mutations. 
This combination regimen is thus a good alternative or 
bridge therapy for patients with multi-drug resistance until 
tenofovir become available. Further studies with larger 
number of patients are needed to determine the exact 
efficacy of this regimen and the factors that favor a good 
IVR. 
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Appendix Table 1. Baseline factors associated with an IVR (defined as a 2  log decrease from the baseline)
Patients with IVR (n=15) 
(Group 1)
Patients without IVR
(n=10) (Group 2)
P-value
Median age, years (min-max) 48 (25-59) 55 (46-64) 0.045
No. of males (% of 25) 14 (93) 6 (60) 0.121
Mean serum HBV DNA level 
  Baseline, log10copies/mL (±SD) 6.4 (1.41) 5.5 (0.8) 0.118
  Months 6, log10copies/mL (±SD) 2.9 (1.5) 4.0 (0.6) 0.041
Mean change in serum HBV DNA level
  Months 6, log10copies/mL (±SD) 3.5 (1.4) 1.6 (0.8) 0.001
No. of patients with HBV DNA levels, log10copies/mL
  < 7 . 0  l o g
* 10 9 0.345
  ≥7.0 log 5 1
Median AST (range) 31 (19-403) 38.5 (18-213) 0.723
Median ALT (range) 49 (15-451) 41 (20-172) 0.97
Median albumin g/dL (range) 4.6 (4.4-5.2) 4.4 (4.0-4.8) 0.097
No. of HBeAg-positive patients (%) 12 (80) 8 (80) 1.0
No. with cirrhosis (%) 7 (47) 6 (60) 0.69
No. with biochemical response (%) 12 (80) 7 (70) 0.65
†Previous failures to <3 NAs 9 (60) 5 (50) 0.70
*This standard was taken from Cho et al
14; 
† Number of patients who were exposed to less than 3 NAs.
HBV DNA, hepatitis B virus DNA; IVR, initial virological response; NAs, nucleos(t)ide analogues; AST, aspartate transaminase; 
ALT, alanine transaminase; HBeAg, hepatitis B e-antigen.